Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Establishment of a Monograph
FDA issued an advance notice of proposed rulemaking to establish a monograph for OTC antigingivitis/antiplaque drug products, potentially reclassifying some cosmetic oral care products as drugs, requiring FDA registration, drug listing, and compliance with drug GMPs.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors of oral care products making antigingivitis/antiplaque claims. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 90 days after publication in Federal Register (publication date May 29, 2003).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is proposing to establish a monograph that would define conditions for OTC antigingivitis/antiplaque drug products, potentially reclassifying products currently marketed as cosmetics with drug claims.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors of oral care products making antigingivitis/antiplaque claims.
What you must do
Review product claims and formulations to determine if they fall under the proposed monograph; prepare for potential drug registration and GMP compliance.
Deadline
Comment period ends 90 days after publication in Federal Register (publication date May 29, 2003).
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection